Badreddin  Edris net worth and biography

Badreddin Edris Biography and Net Worth

Director and Co-Founder of Edgewise Therapeutics

Badreddin Edris, Ph.D., is a co-founder of Edgewise Therapeutics and serves as a member of our board of directors after having served as our strategic advisor and in an operational role. Dr. Edris is currently the Chief Operating Officer of SpringWorks Therapeutics (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on rare diseases and cancer. At SpringWorks, Dr. Edris leads the company’s strategic planning, business development, capital formation, investor relations, and competitive intelligence efforts. Prior to joining SpringWorks, Dr. Edris was an investment and operating professional on the private equity team at OrbiMed where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. In addition to Edgewise, Dr. Edris also co-founded Silverback Therapeutics while at OrbiMed and served as the company’s Chief Business Officer. Before OrbiMed, Dr. Edris was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects. Dr. Edris received his Ph.D. in genetics from Stanford University School of Medicine, where he was an NSF research fellow.

What is Badreddin Edris' net worth?

The estimated net worth of Badreddin Edris is at least $587.66 thousand as of January 21st, 2026. Dr. Edris owns 19,820 shares of Edgewise Therapeutics stock worth more than $587,663 as of February 3rd. This net worth evaluation does not reflect any other investments that Dr. Edris may own. Additionally, Dr. Edris receives an annual salary of $43,000.00 as Director and Co-Founder at Edgewise Therapeutics. Learn More about Badreddin Edris' net worth.

How old is Badreddin Edris?

Dr. Edris is currently 37 years old. There are 8 older executives and no younger executives at Edgewise Therapeutics. The oldest executive at Edgewise Therapeutics is Dr. Joanne M. Donovan M.D., Ph.D., Chief Medical Officer, who is 67 years old. Learn More on Badreddin Edris' age.

What is Badreddin Edris' salary?

As the Director and Co-Founder of Edgewise Therapeutics, Inc., Dr. Edris earns $43,000.00 per year. There are 6 executives that earn more than Dr. Edris. The highest earning executive at Edgewise Therapeutics is Dr. Kevin Koch Ph.D., President, CEO & Director, who commands a salary of $905,520.00 per year. Learn More on Badreddin Edris' salary.

How do I contact Badreddin Edris?

The corporate mailing address for Dr. Edris and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Badreddin Edris' contact information.

Has Badreddin Edris been buying or selling shares of Edgewise Therapeutics?

Over the course of the past ninety days, Badreddin Edris has sold $3,399,466.24 of Edgewise Therapeutics stock. Most recently, Badreddin Edris sold 115,471 shares of the business's stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $29.44, for a transaction totalling $3,399,466.24. Following the completion of the sale, the director now directly owns 19,820 shares of the company's stock, valued at $583,500.80. Learn More on Badreddin Edris' trading history.

Who are Edgewise Therapeutics' active insiders?

Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Badreddin Edris (Director and Co-Founder), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.

Are insiders buying or selling shares of Edgewise Therapeutics?

During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 507,471 shares worth more than $10,199,448.23. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 355,832 shares worth more than $7,719,320.55. The most recent insider tranaction occured on January, 21st when Director Badreddin Edris sold 115,471 shares worth more than $3,399,466.24. Insiders at Edgewise Therapeutics own 23.2% of the company. Learn More about insider trades at Edgewise Therapeutics.

Information on this page was last updated on 1/21/2026.

Badreddin Edris Insider Trading History at Edgewise Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/21/2026Sell115,471$29.44$3,399,466.2419,820View SEC Filing Icon  
See Full Table

Badreddin Edris Buying and Selling Activity at Edgewise Therapeutics

This chart shows Badreddin Edris's buying and selling at Edgewise Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Edgewise Therapeutics Company Overview

Edgewise Therapeutics logo
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $29.65
Low: $28.60
High: $29.98

50 Day Range

MA: $25.46
Low: $20.94
High: $29.78

2 Week Range

Now: $29.65
Low: $10.60
High: $30.48

Volume

1,028,909 shs

Average Volume

1,092,104 shs

Market Capitalization

$3.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27